The diverse functions of FAT1 in cancer progression: good, bad, or ugly?

Abstract FAT atypical cadherin 1 (FAT1) is among the most frequently mutated genes in many types of cancer. Its highest mutation rate is found in head and neck squamous cell carcinoma (HNSCC), in which FAT1 is the second most frequently mutated gene. Thus, FAT1 has great potential to serve as a targ...

Full description

Bibliographic Details
Main Authors: Zhuo Georgia Chen, Nabil F. Saba, Yong Teng
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-022-02461-8
_version_ 1798039007338168320
author Zhuo Georgia Chen
Nabil F. Saba
Yong Teng
author_facet Zhuo Georgia Chen
Nabil F. Saba
Yong Teng
author_sort Zhuo Georgia Chen
collection DOAJ
description Abstract FAT atypical cadherin 1 (FAT1) is among the most frequently mutated genes in many types of cancer. Its highest mutation rate is found in head and neck squamous cell carcinoma (HNSCC), in which FAT1 is the second most frequently mutated gene. Thus, FAT1 has great potential to serve as a target or prognostic biomarker in cancer treatment. FAT1 encodes a member of the cadherin-like protein family. Under normal physiological conditions, FAT1 serves as a molecular “brake” on mitochondrial respiration and acts as a receptor for a signaling pathway regulating cell–cell contact interaction and planar cell polarity. In many cancers, loss of FAT1 function promotes epithelial-mesenchymal transition (EMT) and the formation of cancer initiation/stem-like cells. However, in some types of cancer, overexpression of FAT1 leads to EMT. The roles of FAT1 in cancer progression, which seems to be cancer-type specific, have not been clarified. To further study the function of FAT1 in cancers, this review summarizes recent relevant literature regarding this protein. In addition to phenotypic alterations due to FAT1 mutations, several signaling pathways and tumor immune systems known or proposed to be regulated by this protein are presented. The potential impact of detecting or targeting FAT1 mutations on cancer treatment is also prospectively discussed.
first_indexed 2024-04-11T21:48:00Z
format Article
id doaj.art-b21774db070240a0b4d7c0c62b492bc5
institution Directory Open Access Journal
issn 1756-9966
language English
last_indexed 2024-04-11T21:48:00Z
publishDate 2022-08-01
publisher BMC
record_format Article
series Journal of Experimental & Clinical Cancer Research
spelling doaj.art-b21774db070240a0b4d7c0c62b492bc52022-12-22T04:01:22ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662022-08-0141111110.1186/s13046-022-02461-8The diverse functions of FAT1 in cancer progression: good, bad, or ugly?Zhuo Georgia Chen0Nabil F. Saba1Yong Teng2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of MedicineDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of MedicineDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of MedicineAbstract FAT atypical cadherin 1 (FAT1) is among the most frequently mutated genes in many types of cancer. Its highest mutation rate is found in head and neck squamous cell carcinoma (HNSCC), in which FAT1 is the second most frequently mutated gene. Thus, FAT1 has great potential to serve as a target or prognostic biomarker in cancer treatment. FAT1 encodes a member of the cadherin-like protein family. Under normal physiological conditions, FAT1 serves as a molecular “brake” on mitochondrial respiration and acts as a receptor for a signaling pathway regulating cell–cell contact interaction and planar cell polarity. In many cancers, loss of FAT1 function promotes epithelial-mesenchymal transition (EMT) and the formation of cancer initiation/stem-like cells. However, in some types of cancer, overexpression of FAT1 leads to EMT. The roles of FAT1 in cancer progression, which seems to be cancer-type specific, have not been clarified. To further study the function of FAT1 in cancers, this review summarizes recent relevant literature regarding this protein. In addition to phenotypic alterations due to FAT1 mutations, several signaling pathways and tumor immune systems known or proposed to be regulated by this protein are presented. The potential impact of detecting or targeting FAT1 mutations on cancer treatment is also prospectively discussed.https://doi.org/10.1186/s13046-022-02461-8FAT1Cancer progressionGene mutationsSignaling regulatory networkTargeted treatment
spellingShingle Zhuo Georgia Chen
Nabil F. Saba
Yong Teng
The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
Journal of Experimental & Clinical Cancer Research
FAT1
Cancer progression
Gene mutations
Signaling regulatory network
Targeted treatment
title The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
title_full The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
title_fullStr The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
title_full_unstemmed The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
title_short The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
title_sort diverse functions of fat1 in cancer progression good bad or ugly
topic FAT1
Cancer progression
Gene mutations
Signaling regulatory network
Targeted treatment
url https://doi.org/10.1186/s13046-022-02461-8
work_keys_str_mv AT zhuogeorgiachen thediversefunctionsoffat1incancerprogressiongoodbadorugly
AT nabilfsaba thediversefunctionsoffat1incancerprogressiongoodbadorugly
AT yongteng thediversefunctionsoffat1incancerprogressiongoodbadorugly
AT zhuogeorgiachen diversefunctionsoffat1incancerprogressiongoodbadorugly
AT nabilfsaba diversefunctionsoffat1incancerprogressiongoodbadorugly
AT yongteng diversefunctionsoffat1incancerprogressiongoodbadorugly